Roussot N, Kaderbhai C, Ghiringhelli F
Cancers (Basel). 2025; 17(5).
PMID: 40075753
PMC: 11898530.
DOI: 10.3390/cancers17050906.
Finatto A, Yang C, de Oliveira Costa M
Sci Rep. 2025; 15(1):7568.
PMID: 40038370
PMC: 11880483.
DOI: 10.1038/s41598-025-90688-8.
Dadey R, Cui J, Rajasundaram D, Yano H, Liu C, Cohen J
Immunohorizons. 2025; 9(4).
PMID: 39965167
PMC: 11841976.
DOI: 10.1093/immhor/vlae014.
Di Stasi V, La Sala D, Cozzi R, Scavuzzo F, De Geronimo V, Poggi M
Cancers (Basel). 2025; 17(3).
PMID: 39941803
PMC: 11815778.
DOI: 10.3390/cancers17030436.
Wu R, Zeng M, Zhang Y, He J
Front Oncol. 2025; 14:1514578.
PMID: 39743998
PMC: 11688305.
DOI: 10.3389/fonc.2024.1514578.
Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy.
Hosseininejad-Chafi M, Eftekhari Z, Oghalaie A, Behdani M, Sotoudeh N, Kazemi-Lomedasht F
Med Oncol. 2024; 42(1):36.
PMID: 39719469
DOI: 10.1007/s12032-024-02588-y.
Construction and validation of a regulatory T cells-based classification of renal cell carcinoma: an integrated bioinformatic analysis and clinical cohort study.
Yao Y, Liu Y, Lu B, Ji G, Wang L, Dong K
Cell Oncol (Dordr). 2024; .
PMID: 39714755
DOI: 10.1007/s13402-024-01030-9.
Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials.
Ren K, Hamdy H, Meyiah A, Elkord E
Front Immunol. 2024; 15():1501613.
PMID: 39660130
PMC: 11628531.
DOI: 10.3389/fimmu.2024.1501613.
Neurotrophic factor Neuritin modulates T cell electrical and metabolic state for the balance of tolerance and immunity.
Yu H, Nishio H, Barbi J, Mitchell-Flack M, Vignali P, Zheng Y
Elife. 2024; 13.
PMID: 39565188
PMC: 11578584.
DOI: 10.7554/eLife.96812.
LAG-3-An incompletely understood target in cancer therapy.
Leitner J, Aigner-Radakovics K, Steinberger P
FASEB J. 2024; 38(22):e70190.
PMID: 39560030
PMC: 11698013.
DOI: 10.1096/fj.202401639R.
Monoclonal Antibody against Porcine LAG3 Inhibits Porcine Reproductive and Respiratory Syndrome Virus Infection.
Wang H, Zheng X, Zheng D, Wang X, Zhao Z, Zhao M
Vet Sci. 2024; 11(10).
PMID: 39453075
PMC: 11512405.
DOI: 10.3390/vetsci11100483.
Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements.
Martinez-Perez A, Granda-Diaz R, Aguilar-Garcia C, Sordo-Bahamonde C, Gonzalez S
Biomark Res. 2024; 12(1):126.
PMID: 39425148
PMC: 11487938.
DOI: 10.1186/s40364-024-00671-0.
Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy.
Kamali A, Hamedifar H, Eisenhut M, Bautista J
Ther Adv Vaccines Immunother. 2024; 12:25151355241288453.
PMID: 39399301
PMC: 11467827.
DOI: 10.1177/25151355241288453.
Lymphocyte activation gene 3 served as a potential prognostic and immunological biomarker across various cancer types: a clinical and pan-cancer analysis.
Liu Y, Yao Y, Yang X, Wei M, Lu B, Dong K
Clin Transl Immunology. 2024; 13(10):e70009.
PMID: 39372371
PMC: 11450455.
DOI: 10.1002/cti2.70009.
Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape.
Inocencio J, Mitrasinovic S, Asad M, Parney I, Zang X, Himes B
Front Immunol. 2024; 15:1424396.
PMID: 39346924
PMC: 11427296.
DOI: 10.3389/fimmu.2024.1424396.
Exploring the molecular landscape of lymphocyte activation gene-3: A literature review.
Nie J, Qin X, Tao X, Huang J
Medicine (Baltimore). 2024; 103(39):e39622.
PMID: 39331884
PMC: 11441911.
DOI: 10.1097/MD.0000000000039622.
Surface Immune Checkpoints as Potential Biomarkers in Physiological Pregnancy and Recurrent Pregnancy Loss.
Zych M, Kniotek M, Roszczyk A, Dabrowski F, Jedra R, Zagozdzon R
Int J Mol Sci. 2024; 25(17).
PMID: 39273326
PMC: 11395075.
DOI: 10.3390/ijms25179378.
Advances in understanding the role of immune checkpoint LAG-3 in tumor immunity: a comprehensive review.
Luo Y, Cai X, Yang B, Lu F, Yi C, Wu G
Front Oncol. 2024; 14:1402837.
PMID: 39252941
PMC: 11381248.
DOI: 10.3389/fonc.2024.1402837.
Multi-Layered Mechanisms of Immunological Tolerance at the Maternal-Fetal Interface.
Joo J, Lee D, Hong J
Immune Netw. 2024; 24(4):e30.
PMID: 39246621
PMC: 11377946.
DOI: 10.4110/in.2024.24.e30.
Unlocking therapeutic potential: Targeting lymphocyte activation Gene-3 (LAG-3) with fibrinogen-like protein 1 (FGL1) in systemic lupus erythematosus.
Wang B, Zhang B, Wu M, Xu T
J Transl Autoimmun. 2024; 9:100249.
PMID: 39228513
PMC: 11369448.
DOI: 10.1016/j.jtauto.2024.100249.